Collaboration aims to streamline prostate MRI interpretation, fusion biopsy guidance
With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity 3D Ultrasound Platform for prostate fusion biopsy.
Koelis has announced a partnership with DeepHealth to integrate DeepHealth's AI-powered Prostate software with the Koelis Trinity 3D Ultrasound Platform for streamlined prostate MRI interpretation and prostate fusion biopsy guidance, Koelis announced in a news release.1
The Trinity system is also being utilized in the company’s VIOLETTE study.
The initial experience using both technologies has also been successfully completed.
According to Koelis, “Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the company’s unique prostate motion tracking software (OBT Fusion).” The integration of the DeepHealth software will enable radiologists and urologists to enhance their workflow through seamless integration of automated prostate MRI segmentation into the Trinity platform.
John R. Melnick, MD, medical director at Lenox Hill Radiology in New York, New York, said in the news release, “We have been offering Koelis fusion biopsy at Lenox Hill Radiology since 2020. As the director of prostate imaging, I have been reading and preparing all MRI prior to fusion biopsy. Since Koelis became compatible with DeepHealth Prostate, my job has been tremendously more efficient, not only from the perfect PACS integration of the DeepHealth software, but also from the immediate AI-powered contouring feature it offers.”1
With this integration, imaging data from the DeepHealth software can be readily imported to the Trinity system, where the platform will process the images and create 3D patient-specific maps to provide clinical guidance for diagnostic and treatment procedures. The aim of the collaboration, Koelis notes, is to “access to PACS/cloud connectivity and automated prostate MRI segmentation to be readily imported into the KOELIS Trinity platform.”1
"Always responding and innovating to meet the needs of urologists and their patients, Koelis is excited about announcing this enhancement in the radiology/AI field as well as on our flagship application the transperineal fusion biopsy,” Antoine Leroy, Koelis founder and CEO, concluded in the news release.1 “We strongly believe that our collaboration with DeepHealth will facilitate the adoption of MRI fusion biopsy as a new standard of care in the USA. We are committed to continuously improve our product offering. More possibilities will come in the next months with new radiology partners and organic developments in AI-based productivity.”
Additional info on the Trinity platform
The Trinity system is also being utilized in the company’s VIOLETTE study (NCT04582656), which is assessing Trinity-guided microwave ablation technology for patients with localized intermediate-risk prostate cancer.2 For the trial, the index tumor will be detected with prostate MRI, and the Trinity system will be used to characterize lesions via targeted biopsies with Organ Based Tracking (OBT) fusion. The platform will then assist in identifying and guiding targeted microwave ablation with the TATO3 device.
In total, the prospective, multicenter trial will include up to 65 patients with intermediate-risk prostate cancer. Patients were enrolled across 7 clinical trial sites in Europe. The study will primarily assess the efficacy of Trinity-guided microwave ablation therapy, which may be delivered transperineally or transrectally.
The primary outcome measure for the study is the proportion of patients with no evidence of cancer on targeted biopsy at 12 months. Secondary outcome measures include quality of life and satisfaction measures, as well as safety and other efficacy evaluations.
Reference
1. Koelis announces partnership and initial experience with DeepHealth for AI-powered prostate MRI interpretation and guidance in fusion biopsy. News release. Koelis. September 20, 2024. Accessed September 25, 2024. https://www.globenewswire.com/news-release/2024/09/20/2949710/0/en/Koelis-Announces-Partnership-and-Initial-Experience-with-DeepHealth-for-AI-powered-Prostate-MRI-Interpretation-and-Guidance-in-Fusion-Biopsy.html
2. Efficacy assessment of a novel 3D cartography-based targeted focal microwave therapy in men with localized intermediate-risk prostate cancer (VIOLETTE). ClinicalTrials.gov. Last updated August 6, 2021. Accessed September 25, 2024. https://clinicaltrials.gov/study/NCT04582656
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
PSMA-PET by PROMISE criteria shows prognostic value across prostate cancer continuum
September 20th 2024“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," wrote the authors.
